JP2015500884A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015500884A5 JP2015500884A5 JP2014548915A JP2014548915A JP2015500884A5 JP 2015500884 A5 JP2015500884 A5 JP 2015500884A5 JP 2014548915 A JP2014548915 A JP 2014548915A JP 2014548915 A JP2014548915 A JP 2014548915A JP 2015500884 A5 JP2015500884 A5 JP 2015500884A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- group
- composition according
- mtor inhibitor
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 229940124302 mTOR inhibitor Drugs 0.000 claims 8
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 206010021143 Hypoxia Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 230000007954 hypoxia Effects 0.000 claims 5
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 4
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 4
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 229960005167 everolimus Drugs 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- 229960000235 temsirolimus Drugs 0.000 claims 4
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- RGHYDLZMTYDBDT-UHFFFAOYSA-N 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)-7-pyrido[2,3-d]pyrimidinone Chemical compound O=C1N(CC)C2=NC(N)=NC(C)=C2C=C1C=1C=CNN=1 RGHYDLZMTYDBDT-UHFFFAOYSA-N 0.000 claims 2
- BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 claims 2
- KVLFRAWTRWDEDF-IRXDYDNUSA-N AZD-8055 Chemical group C1=C(CO)C(OC)=CC=C1C1=CC=C(C(=NC(=N2)N3[C@H](COCC3)C)N3[C@H](COCC3)C)C2=N1 KVLFRAWTRWDEDF-IRXDYDNUSA-N 0.000 claims 2
- 206010003571 Astrocytoma Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 125000003435 aroyl group Chemical group 0.000 claims 2
- JROFGZPOBKIAEW-HAQNSBGRSA-N chembl3120215 Chemical compound N1C=2C(OC)=CC=CC=2C=C1C(=C1C(N)=NC=NN11)N=C1[C@H]1CC[C@H](C(O)=O)CC1 JROFGZPOBKIAEW-HAQNSBGRSA-N 0.000 claims 2
- 229950006418 dactolisib Drugs 0.000 claims 2
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims 2
- 201000011519 neuroendocrine tumor Diseases 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 2
- 229960001302 ridaforolimus Drugs 0.000 claims 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 2
- 229960002930 sirolimus Drugs 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 1
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- -1 C 1 -C 6 alkyl Chemical group 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- YUCFVHQCAFKDQG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH] YUCFVHQCAFKDQG-UHFFFAOYSA-N 0.000 claims 1
- 201000000062 kidney sarcoma Diseases 0.000 claims 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161579607P | 2011-12-22 | 2011-12-22 | |
| US61/579,607 | 2011-12-22 | ||
| US201261617579P | 2012-03-29 | 2012-03-29 | |
| US61/617,579 | 2012-03-29 | ||
| PCT/US2012/071070 WO2013096684A1 (en) | 2011-12-22 | 2012-12-20 | Hypoxia activated prodrugs and mtor inhibitors for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015500884A JP2015500884A (ja) | 2015-01-08 |
| JP2015500884A5 true JP2015500884A5 (OSRAM) | 2016-02-18 |
Family
ID=48669506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014548915A Withdrawn JP2015500884A (ja) | 2011-12-22 | 2012-12-20 | 癌を治療するための低酸素活性化プロドラッグおよびｍＴＯＲ阻害剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20150005262A1 (OSRAM) |
| EP (1) | EP2793899A4 (OSRAM) |
| JP (1) | JP2015500884A (OSRAM) |
| WO (1) | WO2013096684A1 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2389532T3 (es) | 2005-06-29 | 2012-10-29 | Threshold Pharmaceuticals, Inc. | Profármacos alquilantes de fosforamidato |
| US9254299B2 (en) | 2011-12-22 | 2016-02-09 | Threshold Pharmaceuticals, Inc. | Administration of hypoxia activated prodrugs in combination with Chk1 inhibitors for treating cancer |
| US20160158253A1 (en) | 2013-07-26 | 2016-06-09 | Threshold Pharmaceuticals, Inc. | Treatment of pancreatic cancer with a combination of a hypoxia-activated prodrug and a taxane |
| US10071109B2 (en) | 2013-11-06 | 2018-09-11 | Molecular Templates, Inc. | Predictive biomarker for hypoxia-activated prodrug therapy |
| KR101692150B1 (ko) * | 2015-05-08 | 2017-01-03 | 계명대학교 산학협력단 | m-TOR 복합체 1,2 억제제 및 커큐민을 유효성분으로 포함하는 신장암 예방 또는 치료용 조성물 |
| US20180140584A1 (en) * | 2015-05-13 | 2018-05-24 | Memorial Sloan Kettering Cancer Center | Macropinocytosis in cancer |
| JP2024531479A (ja) | 2021-08-27 | 2024-08-29 | アセンタウィッツ ファーマシューティカルズ リミテッド | 凍結乾燥製剤溶液および凍結乾燥製剤、ならびにそれらの方法および使用 |
| JP7762796B2 (ja) | 2021-08-27 | 2025-10-30 | アセンタウィッツ ファーマシューティカルズ リミテッド | Ｐａｒｐ阻害剤に耐性のある患者のｔｈ－３０２による治療 |
| WO2023174319A1 (zh) | 2022-03-15 | 2023-09-21 | 深圳艾欣达伟医药科技有限公司 | 治疗brca突变癌症患者的方法 |
| EP4509127A1 (en) | 2022-04-15 | 2025-02-19 | Ascentawits Pharmaceuticals, Ltd. | Method for treating cancer by using th-302 alone or in combination with parp inhibitor |
| WO2023226959A1 (zh) | 2022-05-23 | 2023-11-30 | 深圳艾欣达伟医药科技有限公司 | 烷化剂前药与细胞周期抑制剂联用治疗癌症的方法 |
| EP4591866A1 (en) | 2022-09-22 | 2025-07-30 | Ascentawits Pharmaceuticals, Ltd. | Use of hypoxia-activated compound in preparation of medicament for treating cancer patient |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2389532T3 (es) * | 2005-06-29 | 2012-10-29 | Threshold Pharmaceuticals, Inc. | Profármacos alquilantes de fosforamidato |
| US8946275B2 (en) * | 2008-10-21 | 2015-02-03 | Threshold Pharmaceuticals, Inc. | Treatment of cancer using hypoxia activated prodrugs |
| EP2427174A4 (en) * | 2009-05-04 | 2014-01-15 | Santen Pharmaceutical Co Ltd | HEMMER OF THE MTOR SIGNAL PATH FOR THE TREATMENT OF EYE TROUBLE |
| AU2010314905A1 (en) * | 2009-11-06 | 2012-05-24 | Infinity Pharmaceuticals, Inc. | Oral formulations of a hedgehog pathway inhibitor |
| ES2877629T3 (es) * | 2010-07-12 | 2021-11-17 | Immunogenesis Inc | Administración de profármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer |
| US20140072624A1 (en) * | 2011-04-15 | 2014-03-13 | Threshold Pharmaceuticals, Inc. | Unit dose form for oral administration |
-
2012
- 2012-12-20 JP JP2014548915A patent/JP2015500884A/ja not_active Withdrawn
- 2012-12-20 US US14/367,152 patent/US20150005262A1/en not_active Abandoned
- 2012-12-20 WO PCT/US2012/071070 patent/WO2013096684A1/en not_active Ceased
- 2012-12-20 EP EP12859382.9A patent/EP2793899A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015500884A5 (OSRAM) | ||
| JP2015500885A5 (OSRAM) | ||
| JP2018533611A5 (OSRAM) | ||
| CY1117067T1 (el) | Η χρηση σωματιδιων στερεων φορεων για τη βελτιωση της επεξεργασιμοτητας φαρμακευτικου παραγοντα | |
| JP2008535902A5 (OSRAM) | ||
| EA201000091A1 (ru) | ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K | |
| PE20090506A1 (es) | DERIVADOS DE IMIDAZO-[1,2-b]-PIRIDAZIN COMO INHIBIDORES DE ALK5 Y/O ALK4 | |
| PH12013501594A1 (en) | Substituted indazole derivatives active as kinase inhibitors | |
| EA201000092A1 (ru) | Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний | |
| EA201000090A1 (ru) | Тризамещенные производные пиримидина для лечения пролиферативных заболеваний | |
| PH12016501394A1 (en) | Compounds for treating patients with ros1 mutant cancer cells | |
| WO2009155121A3 (en) | Inhibitors of pi3 kinase | |
| WO2009007749A3 (en) | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases | |
| WO2019035914A8 (en) | Macrocyclic mcl-1 inhibitors and methods of use | |
| ATE514699T1 (de) | Substituierte pyrrolopyrazolderivate als kinaseinhibitoren | |
| HK1211942A1 (en) | Pyrazolopyrimidine compounds as kinase inhibitors | |
| TW200833693A (en) | Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | |
| SI2324008T1 (sl) | 3,4-diarilpirazoli kot protein-kinazni inhibitorji | |
| RU2017104909A (ru) | Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства | |
| MX2010003868A (es) | Cis-imidazolinas quirales. | |
| MX386542B (es) | Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen. | |
| EA201391486A1 (ru) | Способы и композиции для лечения болезни паркинсона | |
| MX2010007714A (es) | Piridinas fusionadas activas como inhibidores de c-met. | |
| WO2008068507A3 (en) | 2 -phenylamino, 6- (pyrid-3-yl) quinazoline derivatives as raf-protein kinase inhibitors in cancer treatment | |
| RU2013146659A (ru) | Способы лечения рака |